This finding demonstrates the efficacy of FZD4/LRP5 agonists in a mouse model of CE and reinforces the concept that the norrin/FZD4 signaling pathway is a highly suitable target for pharmacological intervention in ME. The gene discussed is LRP5; the disease is cholesteryl ester measurement.